Educational strategies including pamphlets and recommendations from family physicians and support from a specialist can improve bone care in men with prostate cancer undergoing androgen deprivation therapy.
Dual HER2 blockade with lapatinib and trastuzumab plus AI therapy was more effective than trastuzumab plus AI alone in HER2+, HR+ metastatic breast cancer.
A study found familial clustering of urothelial cancers, with increased risk of bladder cancer and others, in first- and second-degree relatives of these patients.
Toxicities from buparlisib make it a poor option for patients with HR-positive, HER2-negative advanced breast cancer who progressed on mTOR inhibitor therapy.
The use of bipolar androgen therapy was safe and resulted in responses to enzalutamide in metastatic castration-resistant prostate cancer patients after initial therapy.
Cardiac effects of pertuzumab and trastuzumab following chemotherapy in the neoadjuvant setting were limited for HER2-positive breast cancer patients.
The FDA has granted priority review status to rucaparib as maintenance therapy for women with recurrent ovarian cancer, according to the drug’s developer.
The addition of pazopanib to paclitaxel failed to improve outcomes over paclitaxel alone in women with persistent or recurrent epithelial ovarian cancer.
Patients with metastatic colorectal cancer and high expression of VEGF-D garner more benefit from the VEGFR-2 antibody ramucirumab than those with low VEGF-D expression, according to a new study.
A large meta-analysis found that current and former smoking status was associated with poorer colorectal cancer prognosis compared with never smoking, and that smoking cessation may improve survival over those who continue to smoke.